{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:38:33Z","timestamp":1788349113985,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.schres.2020.12.020","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:41:33Z","timestamp":1614645693000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Peripheral immune markers and antipsychotic non-response in psychosis"],"prefix":"10.1016","volume":"230","author":[{"given":"Daniela","family":"Enache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Nikkheslat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Fathalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paul","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sh\u00f4n","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Deakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.12.020_bb0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"10.1016\/j.schres.2020.12.020_bb0010","first-page":"97","article-title":"Mortality and the relationship of somatic comorbidities to mortality in schizophrenia","volume":"45","author":"Bitter","year":"2017","journal-title":"A nationwide matched-cohort study. European Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0015","series-title":"Associations between non-neurological autoimmune disorders and","author":"Cullen","year":"2018"},{"key":"10.1016\/j.schres.2020.12.020_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09629350123895","article-title":"Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment","volume":"10","author":"Erba\u011fci","year":"2001","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.schres.2020.12.020_bb0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbi.2018.05.002","article-title":"Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study","volume":"71","author":"Frydecka","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.12.020_bb0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2018.07.019","article-title":"Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: new data and an updated meta-analysis","volume":"202","author":"Gallego","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2567.1996.d01-756.x","article-title":"Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes","volume":"89","author":"Gasque","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.schres.2020.12.020_bb0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ng.940","article-title":"study identifies five new schizophrenia loci","volume":"43","author":"Genome-wide association","year":"2011","journal-title":"Nature Genetics"},{"key":"10.1016\/j.schres.2020.12.020_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0050","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0055","article-title":"Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis","author":"Goldsmith","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.12.020_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2018.02.048","article-title":"TNF-alpha and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia","volume":"199","author":"Goldsmith","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2015.06.016","article-title":"Longitudinal regional brain volume loss in schizophrenia: relationship to antipsychotic medication and change in social function","volume":"168","author":"Guo","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jlb.56.5.559","article-title":"Essential involvement of interleukin-8 (IL-8) in acute inflammation","volume":"56","author":"Harada","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.schres.2020.12.020_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2020.12.020_bb0080","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat. Med."},{"key":"10.1016\/j.schres.2020.12.020_bb0085","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand. J. Stat."},{"key":"10.1016\/j.schres.2020.12.020_bb0090","doi-asserted-by":"crossref","unstructured":"Hori, H., Yoshimura, R., Katsuki, A., Atake, K., Igata, R., Konishi, Y., Nakamura, J., 2017. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. The World Journal of Biological Psychiatry18, 401\u2013408. doi:https:\/\/doi.org\/10.1080\/15622975.2016.1212172.","DOI":"10.1080\/15622975.2016.1212172"},{"key":"10.1016\/j.schres.2020.12.020_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.12.020_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1192\/bjp.172.5.413","article-title":"Randomised controlled trial of compliance therapy. 18-Month follow-up","volume":"172","author":"Kemp","year":"1998","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/sj.mp.4001084","article-title":"The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs","volume":"7","author":"Kim","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0120","article-title":"Complement system biomarkers in first episode psychosis","author":"Kopczynska","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(96)02915-0","article-title":"Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs","volume":"66","author":"Maes","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1358\/dnp.2008.21.4.1213349","article-title":"The complement system in schizophrenia","volume":"21","author":"Mayilyan","year":"2008","journal-title":"Drug News & Perspectives"},{"key":"10.1016\/j.schres.2020.12.020_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2020.12.020_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2008.02.004","article-title":"IL-10 modulates depressive-like behavior","volume":"43","author":"Mesquita","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/npp.2016.211","article-title":"Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions","volume":"42","author":"Miller","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.12.020_bb0155","doi-asserted-by":"crossref","first-page":"100006","DOI":"10.1016\/j.bionps.2019.100006","article-title":"Inflammatory biomarkers in schizophrenia: implications for heterogeneity and neurobiology","volume":"1","author":"Miller","year":"2019","journal-title":"Biomarkers in Neuropsychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0165","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4088\/JCP.10m06745","article-title":"Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume","volume":"72","author":"Mondelli","year":"2011","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0170","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.12.020_bb0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2215-0366(17)30101-3","article-title":"Brain microglia in psychiatric disorders","volume":"4","author":"Mondelli","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2020.01.014","article-title":"Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis","author":"Mondelli","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.12.020_bb0185","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"Muller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.12.020_bb0190","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/mp.2017.151","article-title":"The complement system: a gateway to gene\u2013environment interactions in schizophrenia pathogenesis","volume":"22","author":"Nimgaonkar","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","article-title":"High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance","volume":"16","author":"Noto","year":"2015","journal-title":"The World Journal of Biological Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0200","article-title":"A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis","author":"Pillinger","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.12.020_bb0205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0210","first-page":"908468","article-title":"Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis","volume":"2011","author":"Qazi","year":"2011","journal-title":"Int. J. Inflamm."},{"key":"10.1016\/j.schres.2020.12.020_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2202-12-13","article-title":"Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls","volume":"12","author":"Reale","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.schres.2020.12.020_bb0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.schres.2020.12.020_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2014.07.053","article-title":"Maternal complement C1q and increased odds for psychosis in adult offspring","volume":"159","author":"Severance","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0230","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1306326","article-title":"Deficiency in complement factor B","author":"Slade","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2020.12.020_bb0235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.12.020_bb0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2015.10.038","article-title":"Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia","volume":"169","author":"Tan","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0245","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/mp.2016.90","article-title":"Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review","volume":"21","author":"Trepanier","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(96)00037-0","article-title":"Acute phase proteins in male Chinese schizophrenic patients in Singapore","volume":"22","author":"Wong","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-019-0479-0","article-title":"The complement system in schizophrenia: where are we now and what\u2019s next?","author":"Woo","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0260","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","article-title":"Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology","volume":"46","author":"Xiu","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.psychres.2015.07.029","article-title":"Increased IL-3 serum levels in chronic patients with schizophrenia: associated with psychopathology","volume":"229","author":"Xiu","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.12.020_bb0270","doi-asserted-by":"crossref","first-page":"9233 LP","DOI":"10.1073\/pnas.84.24.9233","article-title":"Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines","volume":"84","author":"Yoshimura","year":"1987","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.schres.2020.12.020_bb0275","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000356536","article-title":"First-episode psychosis: an inflammatory state?","volume":"21","author":"Zajkowska","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.schres.2020.12.020_bb0280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2020.12.020_bb0285","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fnins.2018.00296","article-title":"Altered serum tumor necrosis factor and interleukin-1beta in first-episode drug-naive and chronic schizophrenia","volume":"12","author":"Zhu","year":"2018","journal-title":"Front. Neurosci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:40:40Z","timestamp":1760298040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":57,"alternative-id":["S0920996421000050"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.12.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral immune markers and antipsychotic non-response in psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}